# Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

> **NCT05059327** · PHASE2 · COMPLETED · sponsor: **Noema Pharma AG** · enrollment: 61 (actual)

## Conditions studied

- Tuberous Sclerosis Complex

## Interventions

- **DRUG:** Basimglurant with crossover to Placebo
- **DRUG:** Placebo with crossover to Basimglurant

## Key facts

- **NCT ID:** NCT05059327
- **Lead sponsor:** Noema Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-03
- **Primary completion:** 2025-02-06
- **Final completion:** 2025-04-28
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05059327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05059327, "Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05059327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*